Autoantibodies against HSF1 and CCDC155 as biomarkers of early-Stage, high-grade serous ovarian cancer

Wilson, A, Moffitt, L, Duffield, N, Rainczuk, A, Jobling, T, Plebanski, M and Stephens, A 2018, 'Autoantibodies against HSF1 and CCDC155 as biomarkers of early-Stage, high-grade serous ovarian cancer', Cancer Epidemiology Biomarkers and Prevention, vol. 27, no. 2, pp. 183-192.


Document type: Journal Article
Collection: Journal Articles

Title Autoantibodies against HSF1 and CCDC155 as biomarkers of early-Stage, high-grade serous ovarian cancer
Author(s) Wilson, A
Moffitt, L
Duffield, N
Rainczuk, A
Jobling, T
Plebanski, M
Stephens, A
Year 2018
Journal name Cancer Epidemiology Biomarkers and Prevention
Volume number 27
Issue number 2
Start page 183
End page 192
Total pages 10
Publisher American Association for Cancer Research
Abstract Background: Tumor-directed circulating autoantibodies (AAb) are a well-established feature of many solid tumor types, and are often observed prior to clinical disease manifestation. As such, they May provide a good indicator of early disease development. We have conducted a pilot study to identify novel AAbs as markers of early-stage high-grade serous ovarian cancers (HGSOCs). Methods: A rare cohort of patients with early (FIGO stage Ia-c) HGSOCs for IgG, IgA, and IgM-mediated AAb reactivity using high-content protein arrays (containing 9,184 individual proteins). AAb reactivity against selected antigens was validated by ELISA in a second, independent cohort of individual patients. Results: A total of 184 antigens were differentially detected in early-stage HGSOC patients compared with all other patient groups assessed. Among the six most highly detected "early-stage" antigens, anti-IgA AAbs against HSF1 and anti-IgG AAbs CCDC155 (KASH5; nesprin 5) were significantly elevated in patients with early-stage malignancy. Receiver operating characteristic analysis suggested that AAbs against HSF1 provided better detection of early-stage malignancy than CA125 alone. Combined measurement of anti- HSF1, anti- CCDC155, and CA125 also improved efficacy at higher sensitivity. Conclusions: The combined measurement of anti- HSF1, anti- CCDC155, and CA125 May be useful for early-stage HGSOC detection. Impact: This is the first study to specifically identify AAbs associated with early-stage HGSOC. The presence and high frequency of specific AAbs in early-stage cancer patients warrants a larger scale examination to define their value for early disease detection at primary diagnosis and/or recurrence. Cancer Epidemiol Biomarkers Prev; 27(2); 183-92. 2017 AACR.
Subject Medical and Health Sciences not elsewhere classified
Keyword(s) female reproductive-tract
tumor-associated antigens
secretory immune-system
protein arrays
genital tracts
fallopian-tube
cells
IGA
expression
cystadenofibromas
DOI - identifier 10.1158/1055-9965.EPI-17-0752
Copyright notice © 2017 American Association for Cancer Research.
ISSN 1055-9965
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 2 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 0 times in Scopus Article
Altmetric details:
Access Statistics: 7 Abstract Views  -  Detailed Statistics
Created: Thu, 21 Feb 2019, 12:10:00 EST by Catalyst Administrator
© 2014 RMIT Research Repository • Powered by Fez SoftwareContact us